XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.25.2

Share-based Compensation | 6 Months Ended
--- | ---
Jun. 30, 2025
Share-Based Payment Arrangement [Abstract] |
Share-based Compensation | (8) Share-based Compensation Stock Incentive Plans Prior to its expiration, the Company maintained the 2013 Stock Incentive Plan (as amended, the “2013 Equity Plan”), under which the Company’s employees, officers, and directors were awarded various types of share-based compensation, including options to purchase shares of the Company’s class A common stock, restricted stock units, and other stock-based awards. In May 2023, the 2013 Equity Plan expired and no new awards may be granted under the 2013 Equity Plan, although awards previously granted under the 2013 Equity Plan will continue to remain outstanding in accordance with their terms. The Company maintains the 2023 Equity Incentive Plan (as amended, the “2023 Equity Plan”) under which the Company’s employees, officers, directors, and other eligible participants may be awarded various types of share-based compensation, including options to purchase shares of the Company’s class A common stock, restricted stock units, performance stock units, and other stock-based awards. An aggregate of up to 19,327,030 shares of the Company’s class A common stock were authorized for issuance under the 2023 Equity Plan. As of June 30, 2025, there were 2,878,780 shares of class A common stock reserved and available for future issuance under the 2023 Equity Plan. The 2013 Equity Plan and the 2023 Equity Plan together are referred to herein as the “Stock Incentive Plans.” Stock option awards As of June 30, 2025, there were options to purchase 4,158,290 shares of class A common stock outstanding under the Stock Incentive Plans. The following table summarizes the Company’s stock option activity (in thousands, except per share data and years) for the six months ended June 30, 2025:
|  | Stock Options Outstanding |
|  |  |  |  | Weighted Average |  |  | Aggregate |  |  | Weighted Average |
|  |  |  |  | Exercise Price |  |  | Intrinsic |  |  | Remaining Contractual |
|  | Shares |  |  | Per Share |  |  | Value |  |  | Term (Years) |
Balance as of January 1, 2025 |  |  | 4,956 |  |  | $ | 38.56 |  |  |  |  |  |  |
Granted |  |  | 51 |  |  | $ | 296.15 |  |  |  |  |  |  |
Exercised |  |  | (624 | ) |  | $ | 36.94 |  |  | $ | 196,136 |  |  |  |
Forfeited/Expired |  |  | (225 | ) |  | $ | 46.11 |  |  |  |  |  |  |
Balance as of June 30, 2025 |  |  | 4,158 |  |  | $ | 41.54 |  |  |  |  |  |  |
Exercisable as of June 30, 2025 |  |  | 3,022 |  |  | $ | 38.80 |  |  | $ | 1,104,323 |  |  |  | 5.4 |
Expected to vest as of June 30, 2025 |  |  | 1,136 |  |  | $ | 48.82 |  |  | $ | 403,849 |  |  |  | 7.3 |
Total |  |  | 4,158 |  |  | $ | 41.54 |  |  | $ | 1,508,172 |  |  |  | 5.9 |
Stock options outstanding as of June 30, 2025 are comprised of the following range of exercise prices per share (in thousands, except per share data and years):
|  | Stock Options Outstanding at June 30, 2025 |
|  |  |  |  | Weighted Average |  |  | Weighted Average |
|  |  |  |  | Exercise Price |  |  | Remaining Contractual |
Range of Exercise Prices per Share |  | Shares |  |  | Per Share |  |  | Term (Years) |
$12.45 - $20.00 |  |  | 1,114 |  |  | $ | 15.55 |  |  |  | 4.5 |
$20.01 - $30.00 |  |  | 912 |  |  | $ | 24.59 |  |  |  | 7.0 |
$30.01 - $40.00 |  |  | 23 |  |  | $ | 30.16 |  |  |  | 5.3 |
$40.01 - $50.00 |  |  | 1,171 |  |  | $ | 41.30 |  |  |  | 6.3 |
$50.01 - $70.00 |  |  | 807 |  |  | $ | 69.12 |  |  |  | 5.7 |
$70.01 - $220.00 |  |  | 76 |  |  | $ | 159.52 |  |  |  | 8.6 |
$220.01 - $300.00 |  |  | 41 |  |  | $ | 261.29 |  |  |  | 9.6 |
$300.01 - $364.20 |  |  | 11 |  |  | $ | 364.20 |  |  |  | 9.5 |
$364.21 and over |  |  | 3 |  |  | $ | 369.06 |  |  |  | 9.9 |
Total |  |  | 4,158 |  |  | $ | 41.54 |  |  |  | 5.9 |
An aggregate of 1,161,010 stock options with an aggregate grant date fair value of $34.5 million vested during the six months ended June 30, 2025. An aggregate of 1,384,650 stock options with an aggregate grant date fair value of $37.5 million vested during the six months ended June 30, 2024. The weighted average grant date fair value of stock option awards using the Black-Scholes valuation model was $296.15 and $111.23 for each share subject to a stock option granted during the six months ended June 30, 2025 and 2024, respectively, based on the following assumptions:
|  | Six Months Ended
|  | June 30,
|  | 2025 |  | 2024
Expected term of awards in years |  | 5.5-6.3 |  | 5.5 - 6.3
Expected volatility |  | 83.8% - 91.5% |  | 75.1% - 82.8%
Risk-free interest rate |  | 4.0% - 4.4% |  | 4.2% - 4.5%
Expected dividend yield |  | 0.0% |  | 0.0%
For the three and six months ended June 30, 2025, the Company recognized approximately $5.2 million and $11.8 million, respectively, in share-based compensation expense from stock options granted under the Stock Incentive Plans. For the three and six months ended June 30, 2024, the Company recognized approximately $10.3 million and $20.1 million, respectively, in share-based compensation expense from stock options granted under the Stock Incentive Plans. As of June 30, 2025, there was approximately $29.5 million of total unrecognized share-based compensation expense related to unvested stock options, which the Company expects to recognize over a weighted average vesting period of approximately 2.3 years. Share-settled restricted stock units As of June 30, 2025, there were 880,064 share-settled restricted stock units outstanding under the Stock Incentive Plans. The following table summarizes the Company’s share-settled restricted stock unit activity (in thousands) for the periods indicated:
|  | Share-Settled Restricted Stock Units Outstanding |
|  |  |  |  | Aggregate |
|  | Units |  |  | Intrinsic Value |
Balance as of January 1, 2025 |  |  | 1,231 |  |  |  |
Granted |  |  | 140 |  |  |  |
Vested |  |  | (334 | ) |  | $ | 120,067 |
Forfeited |  |  | (157 | ) |  |  |
Balance as of June 30, 2025 |  |  | 880 |  |  |  |
Expected to vest as of June 30, 2025 |  |  | 880 |  |  | $ | 355,748 |
During the six months ended June 30, 2025, 334,120 share-settled restricted stock units vested having an aggregate grant date fair value of $18.3 million. During the six months ended June 30, 2024, 374,580 share-settled restricted stock units having an aggregate grant date fair value of $11.7 million vested, and 25,060 shares were withheld to satisfy tax obligations, resulting in 349,520 issued shares. The weighted average grant date fair value of share-settled restricted stock units granted during the six months ended June 30, 2025 and 2024 was $281.30 and $145.22, respectively, based on the fair value of the Company’s class A common stock. For the three and six months ended June 30, 2025, the Company recognized approximately $7.1 million and $12.3 million, respectively, in share-based compensation expense from share-settled restricted stock units granted under the Stock Incentive Plans. For the three and six months ended June 30, 2024, the Company recognized approximately $7.4 million and $12.1 million, respectively, in share-based compensation expense from share-settled restricted stock units granted under the Stock Incentive Plans. As of June 30, 2025, there was approximately $74.3 million of total unrecognized share-based compensation expense related to unvested share-settled restricted stock units, which the Company expects to recognize over a weighted average vesting period of approximately 3.0 years. Share-settled performance stock units As of June 30, 2025, there were 279,264 performance stock units outstanding under the 2023 Equity Plan. The following table summarizes the Company’s performance stock unit activity (in thousands) for the periods indicated:
|  | Share-Settled Performance Stock Units Outstanding |
|  |  |  |  | Aggregate |
|  | Units |  |  | Intrinsic Value |
Balance as of January 1, 2025 |  |  | 307 |  |  |  |
Granted |  |  | 24 |  |  |  |
Vested |  |  | 0 |  |  | $ | 0 |
Forfeited |  |  | (52 | ) |  |  |
Balance as of June 30, 2025 |  |  | 279 |  |  |  |
Expected to vest as of June 30, 2025 |  |  | 279 |  |  | $ | 225,774 |
The weighted average grant date fair value of performance stock units using the Monte-Carlo simulation model was $445.66 and $307.13 for each performance stock unit granted during the six months ended June 30, 2025 and 2024, respectively, based on the following assumptions:
|  | Six Months Ended |
|  | June 30, |
|  | 2025 |  |  | 2024 |
Expected term of awards in years |  |  | 3.0 |  |  |  | 3.0 |
Expected volatility |  |  | 99.2 | % |  |  | 92.7 | %
Risk-free interest rate |  |  | 3.9 | % |  |  | 4.4 | %
Expected dividend yield |  |  | 0.0 | % |  |  | 0.0 | %
No performance stock units vested during the six months ended June 30, 2025 and 2024. For the three and six months ended June 30, 2025, the Company recognized approximately $2.7 million and $3.4 million, respectively, in share-based compensation expense from performance stock units granted under the 2023 Equity Plan. For the three and six months ended June 30, 2024, the Company recognized approximately $2.4 million and $3.5 million, respectively, in share-based compensation expense from performance stock units granted under the 2023 Equity Plan. As of June 30, 2025, there was approximately $21.9 million of total unrecognized share-based compensation expense related to unvested performance stock units, which the Company expects to recognize over a weighted average vesting period of approximately 2.1 years. Other stock-based awards and cash-settled restricted stock units From time to time the Company has granted “other stock-based awards” and “cash-settled restricted stock units” under the 2013 Equity Plan. Other stock-based awards are similar to stock options, and cash-settled restricted stock units are similar to the Company’s share-settled restricted stock units, except in each case these awards are settled in cash only and not in shares of the Company’s class A common stock. Due to their required cash settlement feature, these awards are classified as liabilities in the Company’s Consolidated Balance Sheets and the fair value of the awards is remeasured each quarterly reporting period. For the three and six months ended June 30, 2025, the Company recognized zero expense and a reduction of approximately $1.1 million, respectively, in share-based compensation expense from other stock-based awards and cash-settled restricted stock units. For the three and six months ended June 30, 2024, the Company recognized approximately $0.1 million and $1.9 million, respectively, in share-based compensation expense from other stock-based awards and cash-settled restricted stock units. As of June 30, 2025, there were no other stock-based awards or cash-settled restricted stock units outstanding and there was no unrecognized share-based compensation expense. 2021 ESPP The Company also maintains the 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The purpose of the 2021 ESPP is to provide eligible employees of the Company and certain of its subsidiaries with opportunities to purchase shares of the Company’s class A common stock in 6-month offering periods commencing on each March 1 and September 1. An aggregate of 1,000,000 shares of the Company’s class A common stock has been authorized for issuance under the 2021 ESPP. During the six months ended June 30, 2025, 25,998 shares of class A common stock were issued in connection with the 2021 ESPP. As of June 30, 2025, 476,404 shares of the Company’s class A common stock remained available for issuance under the 2021 ESPP. For the three and six months ended June 30, 2025, the Company recognized approximately $0.8 million and $1.2 million, respectively, in share-based compensation expense related to the 2021 ESPP. For the three and six months ended June 30, 2024, the Company recognized approximately $0.4 million and $0.8 million, respectively, in share-based compensation expense related to the 2021 ESPP. As of June 30, 2025, there was approximately $0.5 million of total unrecognized share-based compensation expense related to the 2021 ESPP, which the Company expects to recognize over a period of approximately 0.2 years. Tax Benefits Related to Equity Plans The following table summarizes the tax benefit related to the Company’s equity plans (in thousands) for the three and six months ended June 30, 2025 and 2024:
|  | Three Months Ended |  |  | Six Months Ended |
|  | June 30, |  |  | June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Tax benefit related to: |  |  |  |  |  |  |  |  |  |  |  |
Share-based compensation expense |  | $ | (2,443 | ) |  | $ | (3,887 | ) |  | $ | (4,331 | ) |  | $ | (8,079 | )
Exercises of stock options and vesting of share-settled restricted stock units |  |  | (40,192 | ) |  |  | (52,960 | ) |  |  | (64,797 | ) |  |  | (157,266 | )
Total tax benefit related to the Company's equity plans |  | $ | (42,635 | ) |  | $ | (56,847 | ) |  | $ | (69,128 | ) |  | $ | (165,345 | )

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration